文献速递骨软组织肉瘤与黑色素瘤

普萘洛尔单药治疗血管肉瘤——一项机会窗口研究(PropAngio)

Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio).
PubMed 文献 · Eur J Cancer · 2024-03-02

这项机会窗口研究在14例血管肉瘤患者中评估普萘洛尔单药(80–240 mg/天,3–6周)抗肿瘤活性,主要终点为至少3例临床缓解。结果显示2例(14%,95%CI 3–100%)临床缓解,无组织学缓解,常见不良事件为1/2级心动过缓(86%),无≥3级不良事件,ADRB1/2表达与临床缓解无关。

要点

  • 普萘洛尔单药在14例血管肉瘤中2例(14%)达临床缓解,未达主要终点。
  • 中位治疗26天(范围21–42天),中位最高剂量160 mg/天(范围80–240 mg)。
  • 常见不良事件为1/2级心动过缓(86%),无≥3级不良事件。

核心结论

  • 此机会窗口试验未显示普萘洛尔单药治疗血管肉瘤的临床疗效,但14例中2例显示临床获益,ADRB1/2表达与临床缓解不相关。

研究设计与样本

  • 机会窗口试验,前瞻性评估普萘洛尔单药在血管肉瘤患者标准治疗前的抗肿瘤活性。
  • 共纳入14例患者,普萘洛尔按剂量滴定方案给药80–240 mg/天,持续3–6周。
  • 主要终点为至少3例患者达到临床缓解(RECIST 1.1缓解或皮肤病变改善的疾病稳定)。
  • 探索性目标包括组织学缓解(Ki-67下降>30%)、FDG PET缓解和β受体表达水平。

主要发现

  • 中位治疗持续时间为26天(范围21–42天),中位最高普萘洛尔剂量为160 mg/天(范围80–240 mg)。
  • 2例患者显示临床缓解(14%,95%CI 3–100%),其中1例在PET-CT上显示部分代谢缓解。
  • 无肿瘤显示组织学缓解。
  • 最常见不良事件为1/2级心动过缓(86%),无≥3级不良事件。
  • ADRB2在18个肿瘤中的16个过表达,缓解者和非缓解者均如此;无肿瘤显示ADRB1过表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiosarcoma is a rare and aggressive cancer of the endothelial cells. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been described in several case reports. The aim of this trial was to prospectively evaluate the anti-tumor activity of propranolol monotherapy in patients with angiosarcoma before proceeding to standard of care treatment. METHODS: Propranolol was dosed 80 mg to 240 mg/day for 3 to 6 weeks according to a dose titration schedule. The primary endpoint was clinical response (response according to RECIST 1.1 or stable disease with improvement of cutaneous lesions) in at least three patients. Exploratory objectives included histologic response (>30% decrease in Ki-67), FDG PET response, and β-receptor expression levels. RESULTS: Fourteen patients were enrolled. The median duration of treatment was 26 days (range 21-42 days). The median highest propranolol dose was 160 mg/day (range 80 - 240 mg). Two patients showed clinical response (14%, 95% CI 3-100%). One of these patients showed a partial metabolic response on PET-CT. None of the tumors showed histologic response. The most common adverse event was grade 1/2 bradycardia (86%). There were no grade ≥ 3 adverse events. ADRB2 was overexpressed in 16 out of 18 tumors, in both responders and non-responders. None of the tumors showed ADRB1 overexpression. CONCLUSIONS: This window-of-opportunity trial did not show clinical efficacy of propranolol monotherapy. However, two out of 14 patients did show clinical benefit. ADRB1/2 expression did not correlate with clinical response.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Embaby A, Heinhuis KM, IJzerman NS, et al. Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio). Eur J Cancer. 2024. PMID: 38452721. doi:10.1016/j.ejca.2024.113974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。